drugset / Trial / NCT00730821
Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors
Treatment
Summary
The primary objective of this trial is to determine the MTD of the combination of BIBW 2992/BIBF 1120 therapy administered concomitantly in a 28-day cycle schedule. Secondary objectives are the collection of antitumor efficacy data, the determination of pharmacokinetic parameters of BIBF 1120 and BIBW 2992, and if data allow the determination of the pharmacokinetic influence of BIBW 2992 on BIBF 1120 and vice versa.
Timeline
- Start
- 2007-01
- Primary completion
- 2009-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afatinib | Small molecule | — | — |
| Subject | Nintedanib | Small molecule | — | — |